Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards
Scott R. Evans, Thomas R. Fleming, Holly Janes, Lori E. Dodd
原始摘要（英文原文）· Original abstract
This Perspective discusses the use of bayesian methods in clinical trials and the importance of having US Food and Drug Administration (FDA) guidance that provides substantive insights about the methods’ proper role.